(Q54066504)

24 May 2018

title

Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study. (English)

1 reference

24 May 2018

levobunolol hydrochloride

main subject

1 reference

ChEBI release 2020-05-28

3

1 reference

24 May 2018

author name string

Derick RJ

1

1 reference

24 May 2018

Robin AL

2

1 reference

24 May 2018

Wexler JL

4

1 reference

24 May 2018

Kelley EP

5

1 reference

24 May 2018

Stoecker JF

6

1 reference

24 May 2018

Novack GD

7

1 reference

24 May 2018

Coleman AL

8

1 reference

24 May 2018

publication date

1 March 1992

1 reference

24 May 2018

published in

Ophthalmology

1 reference

24 May 2018

volume

99

1 reference

24 May 2018

issue

3

1 reference

24 May 2018

page(s)

424-429

1 reference

24 May 2018

A dose-response study of the effect of levobunolol on ocular hypertension

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Levobunolol vs timolol for open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Long-term ocular hypotensive effect of levobunolol: results of a one-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Levobunolol compared with timolol for the long-term control of elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Timolol maleate: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

The effects of withdrawal of timolol in chronically treated glaucoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Plasma levobunolol levels following topical administration with reference to systemic side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

The effect of enalapril and timolol on blood lipids. A randomized multicenter hypertension study in general practice in Norway.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Glaucoma treatment with once-daily levobunolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Glaucoma treatment with once-daily levobunolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Metabolism of l-bunolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Binding of the beta-blockers timolol and H 216/44 to ocular melanin

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Long-term drift and continued efficacy after multiyear timolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Topical timolol decreases plasma high-density lipoprotein cholesterol level.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

Compliance with topical timolol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931957-8

7 January 2021

10.1016/S0161-6420(92)31957-8

Identifiers

DOI

1 reference

24 May 2018

PubMed ID

1565455

1 reference

24 May 2018